Phost’in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona

Montpellier, France – June 2022, 7th

Phost’in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, today announced the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Italian Medicines Agency (AIFA) have accepted an adaptive Phase I/II in patients with advanced solid tumors for the First-In-Class selective n-glycosylation inhibitor, PhOx430 (the PhAST trial).